-+ 0.00%
-+ 0.00%
-+ 0.00%

Ultragenyx Pharmaceuticals shares fell 42.6% in pre-market trading after an advanced trial of a drug to treat bone disease failed.

Zhitongcaijing·12/29/2025 14:09:04
Listen to the news
Ultragenyx Pharmaceuticals shares fell 42.6% in pre-market trading after an advanced trial of a drug to treat bone disease failed.